首页> 外文期刊>BMC Psychiatry >Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients
【24h】

Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients

机译:初次服用药物的精神分裂症患者的谷胱甘肽水平降低和抗氧化酶活性受损

获取原文
获取外文期刊封面目录资料

摘要

Background The aim of this study was to determine glutathione levels and antioxidant enzyme activities in the drug-naive first-episode patients with schizophrenia in comparison with healthy control subjects. Methods It was a case-controlled study carried on twenty-three patients (20 men and 3 women, mean age = 29.3 ± 7.5 years) recruited in their first-episode of schizophrenia and 40 healthy control subjects (36 men and 9 women, mean age = 29.6 ± 6.2 years). In patients, the blood samples were obtained prior to the initiation of neuroleptic treatments. Glutathione levels: total glutathione (GSHt), reduced glutathione (GSHr) and oxidized glutathione (GSSG) and antioxidant enzyme activities: superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT) were determined by spectrophotometry. Results GSHt and reduced GSHr were significantly lower in patients than in controls, whereas GSSG was significantly higher in patients. GPx activity was significantly higher in patients compared to control subjects. CAT activity was significantly lower in patients, whereas the SOD activity was comparable to that of controls. Conclusion This is a report of decreased plasma levels of GSHt and GSHr, and impaired antioxidant enzyme activities in drug-naive first-episode patients with schizophrenia. The GSH deficit seems to be implicated in psychosis, and may be an important indirect biomarker of oxidative stress in schizophrenia early in the course of illness. Finally, our results provide support for further studies of the possible role of antioxidants as neuroprotective therapeutic strategies for schizophrenia from early stages.
机译:背景技术这项研究的目的是确定与健康对照组相比,初次服用精神分裂症的初发精神分裂症患者的谷胱甘肽水平和抗氧化酶活性。方法这是一项病例对照研究,研究对象为精神分裂症首发的23例患者(20例男性和3例女性,平均年龄= 29.3±7.5岁)和40例健康对照者(36例男性和9例女性,平均年龄= 29.6±6.2岁)。在患者中,血液样本是在开始精神抑制治疗之前获得的。谷胱甘肽水平:总谷胱甘肽(GSHt),还原型谷胱甘肽(GSHr)和氧化型谷胱甘肽(GSSG)和抗氧化酶活性:通过分光光度法测定超氧化物歧化酶(SOD),谷胱甘肽过氧化物酶(GPx),过氧化氢酶(CAT)。结果患者的GSHt和降低的GSHr显着低于对照组,而GSSG显着高于患者。与对照组相比,患者的GPx活性明显更高。患者的CAT活性明显较低,而SOD活性与对照组相当。结论:这是关于初次服用精神分裂症的初发患者血浆GSHt和GSHr降低,抗氧化酶活性受损的报道。 GSH缺陷似乎与精神病有关,并且可能是精神分裂症在病程早期氧化应激的重要间接生物标志物。最后,我们的结果为从早期开始就抗氧化剂作为精神分裂症的神经保护性治疗策略的可能作用的进一步研究提供了支持。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号